Cameron Turtle - Nov 22, 2023 Form 4 Insider Report for Spyre Therapeutics, Inc. (AGLE)

Role
Chief Executive Officer, Director
Signature
/s/ Heidy King-Jones, as Attorney-in-Fact
Stock symbol
AGLE
Transactions as of
Nov 22, 2023
Transactions value $
$0
Form type
4
Date filed
11/27/2023, 04:25 PM
Previous filing
Jun 30, 2023
Next filing
Feb 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGLE Common Stock Conversion of derivative security $0 +723K +3136.26% $0.00 747K Nov 24, 2023 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGLE Stock Option (Right to Buy) Award $0 +374K $0.00 374K Nov 22, 2023 Common Stock 374K $10.39 Direct F4
transaction AGLE Series A Preferred Stock Conversion of derivative security $0 -18.1K -100% $0.00* 0 Nov 24, 2023 Common Stock 723K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain limitations.
F2 Includes 506,440 shares of common stock that vest over an approximately three year period, subject to the continuing service of the Reporting Person on each vesting date.
F3 Includes 522,588 shares of common stock that vest over an approximately three year period, subject to the continuing service of the Reporting Person on each vesting date.
F4 This option represents a right to purchase 374,000 shares of the Issuer's common stock, one quarter of which will vest and become exercisable on November 22, 2024, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer at each vesting date.